Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS2145214 A
Publication typeGrant
Publication dateJan 24, 1939
Filing dateMar 3, 1936
Publication numberUS 2145214 A, US 2145214A, US-A-2145214, US2145214 A, US2145214A
InventorsDavid Walker Jayne
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Parasiticide
US 2145214 A
Abstract  available in
Images(1)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

Patented Jan. 24, 1939 rmsmcmn David Walker Jayne, Jr., Elizabeth, N. 1., assignor to American Cyanamid Company, New York, N. Y., a corporation of Maine No Drawing. Application March 3, 1936, Serial No. 66,797

12 Claims. (Cl. 16737) This invention relates to a composition for treating fibrous materials such as wool against attack by moths and constitutes an improvement upon the subject matter of U. S. Patent 1,915,922. y In that patent, there has been proposed the treatment of fibrous material for the stated purpose with fatty acid salts of xii-substituted guanidines, specifically dixylyl guanidines. The procedure there proposed is to dissolve such material in a suitable solvent, such as a petroleum fraction and specifically naphtha. The wool or other fibrous material to be protectedis then treated with this solution, and the solvent permitted to evaporate.

When treating fibrous material with. the material of the above patent as above set forth, it.

has been found that in some instances the fibrous material has a greasy appearance or is greasy to the touch. This is due to the fact that the guanidine is used as a fatty acid salt.

The principal object of the present invention, therefore, is to take advantage of the mothproofing qualities of the di-substituted guanidines using, however, salts thereof which are not subject to the above objection but which, at the same time, are as good or better for the purpose specified.

It has been found that the phenolic salts of the di-substituted guanidines are particularly effective as mothproofing agents. Any di-substituted guanidine may be used as the base for the composition and particularly the diaryl compounds. Dixylyl guanidine is preferred.

$ Any of the hydroxy aryl salts of the di-substituted guanidines may be used for this purpose or the hydroxy alkyl aryl salts thereof. I particularly prefer a para tertiary alkyl phenolic salt such as the para tertiary amyl phenolic salt of 40 dimlyl guanidine because ofqtheir greater efllciency. Whichever salt is used, it is preferred to dissolve this material in a petroleum fraction such as naphtha or other solvent which may be readily evaporated.-

As a specific example of preparation of the materlal, three parts of dixylyl guanidine and two parts of para tertiary amyl phenol are mixed together and heated to to C. The mixture is then stirred at this temperatureuntil a clear 50 homogeneous resinous product is obtained. This product is the para tertiary amyl phenol salt of dixylyl guanidine. Ten parts of this material are then dissolved in 8 parts of monobutyl ether of ethylene glycol and this solution diluted with 182 parts of petroleum naphtha to give a solution to be used for mothproofing containing 5% 5 of the guanidine salt. This solution should then be applied to the fibrous material in the proportion of approximately 1 pound of the solution to 20 to 40 pounds of the fibrous material to give desirable mothproofing protection. The solvents 10 are then allowed to evaporate.

While the invention has been shown and described with reference to certain specific embodiments, it is to be understood that the invention is not to be limited thereto but is to be construed l5 broadly and limited only by the scope of the claims.

I claim:

1. A mothproofing composition containing a phenolic salt of a disubstituted guanidine. 20

2. A mothproofing composition containing a phenolic salt of a diaryl guanidine.

3. A mothproofing composition containing a phenolic salt of a dixylyl guanidine.

4. A mothproofing composition containing hydroxy aryl salt of a diaryl guanidine.

5. A mothproofing composition containing a hydroxy alkyl aryl salt of a diaryl guanidine.

6. A mothproofing composition containing a para tertiary alkyl phenolic salt of a diaryl guan- 3o idine.

7. A mothproofing composition .containing a para tertiary amyl phenolic salt of a diaryl guanidine.

8. A mothproofing composition containing a 35 para tertiary alkyl phenolic salt of a dixylyl guanidine.

9. A mothproofing composition containing a para tertiary amyl phenolic salt of dixylyl guanidine. I 40 10. A mothproofing composition containing a phenolic salt of a disubstituted guanidine in a volatile solvent.

11. A mothproofing composition containing a para tertiary amyl phenolic salt of dixylyl guani- 45 dine in a volatile solvent.

12. A mothproofing composition containing a para tertiary alkyl phenolic salt of dixylyl guani dine in a volatile solvent.

navm warm JAYNE, JR.

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US2499226 *Nov 23, 1944Feb 28, 1950American Cyanamid CoResinous aromatic acid salts of a guanidine as mothproofers
US5262568 *Mar 4, 1991Nov 16, 1993State Of OregonTri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5312840 *Feb 25, 1993May 17, 1994State Of Oregon, Acting By And Through The Oregon State Board Of Higher EducationSubstituted guanidines having high binding to the sigma receptor and the use thereof
US5336689 *Aug 11, 1993Aug 9, 1994State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of OregonTri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5385946 *Feb 23, 1993Jan 31, 1995State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of OregonAdministering hypotensive agents
US5403861 *Feb 10, 1992Apr 4, 1995Cambridge Neuroscience, Inc.Treating or preventing nerve cell death
US5478863 *Feb 23, 1993Dec 26, 1995State Of Oregon, Oregon Health Sciences University Of OregonSubstituted guanidines having high binding to the sigma receptor and the use thereof
US5502255 *Feb 23, 1993Mar 26, 1996State Of Oregon Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of OregonSubstituted guanidines having high binding to the sigma receptor and the use thereof
US5559154 *Aug 11, 1993Sep 24, 1996Oregon State Board Of Higher EducationTri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5574070 *May 22, 1991Nov 12, 1996State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences UniversitySubstituted guanidines having high binding to the sigma receptor and the use thereof
US5604228 *Apr 12, 1994Feb 18, 1997State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences UniversitySubstituted guanidines having high binding to the sigma receptor and the use thereof
US5614630 *Jun 5, 1995Mar 25, 1997Cambridge Neuroscience, Inc.Neurotransmitter release modulator
US5622968 *Jun 5, 1995Apr 22, 1997Cambridge Neuroscience, Inc.Acenaphthyl substituted guanidines and methods of use thereof
US5637622 *May 22, 1995Jun 10, 1997State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of OregonNervous system disorders
US5637623 *Jun 6, 1995Jun 10, 1997Cambridge Neuroscience, Inc.Substituted adamantyl guanidines and methods of use there of
US5652269 *Jun 5, 1995Jul 29, 1997Cambridge Neuroscience, Inc.Substituted hydrazinecarboximidamides and methods of use thereof
US5670519 *Jun 5, 1995Sep 23, 1997Cambridge Neuroscience, Inc.Acenaphthyl-substituted guanidines and methods of use thereof
US5672608 *Nov 22, 1994Sep 30, 1997Cambridge Neuroscience, Inc.Acenaphthyl substituted guanidines and methods of use thereof
US5677348 *Jun 5, 1995Oct 14, 1997Cambridge Neuroscience, Inc.Substituted aminoguanidines and methods of use thereof
US5681861 *Jun 6, 1995Oct 28, 1997Cambridge Neuroscience, Inc.Aminoguanidines and methods of use of same
US5686495 *Jun 6, 1995Nov 11, 1997Cambridge Neuroscience, Inc.Substituted hydrazinedicarboximidamides and methods of use thereof
US5741661 *Jun 5, 1995Apr 21, 1998Cambridge Neuroscience, Inc.Screening assay
US5767162 *Jun 6, 1995Jun 16, 1998State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of OregonTri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5798390 *May 22, 1995Aug 25, 1998State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of OregonTri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5837737 *Jun 7, 1995Nov 17, 1998Cambridge Neuroscience, Inc.Hydrazinedicarboximidamide compounds and pharmaceutical composition comprising same
US5847006 *May 31, 1995Dec 8, 1998Cambridge Neuroscience, Inc.Therapeutic guanidines
US5955507 *Jun 2, 1995Sep 21, 1999Cambridge Neuroscience, Inc.Therapeutic substituted guanidines
US6013675 *Jun 2, 1995Jan 11, 2000Cambridge Neuroscience, Inc.Therapeutic substituted guanidines
US6071969 *Jun 5, 1995Jun 6, 2000Cambridge Neuroscience, Inc.Substituted aminoguanidines and methods of use thereof
US6143791 *Jun 7, 1995Nov 7, 2000Cambridge Neuroscience, Inc.Therapeutic guanidines
US6147063 *Jun 2, 1995Nov 14, 2000Cambridge Neuroscience, Inc.Therapeutic substituted guanidines
US6153604 *Jun 2, 1995Nov 28, 2000Cambridge Neuroscience, Inc.Treating disease of nervous system in which pathophysiology of disorder involves excessive excitation of nerve cells by agonists of nmda receptors, comprising administering to guanidine derivative
US6156741 *Jun 2, 1995Dec 5, 2000Cambridge Neuroscience, Inc.Nervous system disorders
US6174924Jun 5, 1995Jan 16, 2001Cambridge Neuroscience, Inc.Treating nerve cell death comprising administering to a subject exhibiting symptoms of nerve cell death or susceptible to nerve cell death a substituted guanidine compound
US6251948Jun 6, 1995Jun 26, 2001State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of OregonTrisubstituted guanidine useful for treating diseases of the nervous system in which the pathophysiology of the disease involves excessive excitation of nerve cells by agonists of glutamate/n-methyl-d-aspartate receptor
US6288123Jun 5, 1995Sep 11, 2001Cambridge Neurosciences, Inc.Therapeutic guanidines
US6787569Aug 11, 2000Sep 7, 2004Cambridge Neuroscience, Inc.Therapeutic guanidines
US7351743Aug 11, 2000Apr 1, 2008WyethTherapeutic guanidines
Classifications
U.S. Classification514/634, 564/239
Cooperative ClassificationA61K31/155